Renal Biomarkers Market, By Biomarker Type (Functional Biomarker, Up-Regulated Proteins, Others), By Technique, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Chronic kidney disease (CKD) involves gradual loss of functioning of kidneys. The normal function of kidneys are to filter out and excrete wastes, and excess fluids from the blood are excreted through urine. However, when an individual is suffering from chronic kidney disease, kidneys cannot perform their natural function and wastes, fluids, and electrolytes build up in the body in excess amounts. Signs and symptoms of chronic kidney disease are not apparent until kidney function becomes significantly impaired. For this purpose various diagnostic tests are performed which involve use of various tests which asses biomarkers to understand functioning of the kidneys. Increase or decrease in values of these biomarkers indicates dysfunction of kidneys.

Restraints of the Global Renal Biomarkers Market

Factors such as low sensitivity and specificity of biomarkers is expected to hinder growth of the global renal biomarkers market. For instance, some renal biomarkers such as L-18 are more specific although are not very sensitive, while other biomarkers such as osteopontin are highly sensitive though they are not specific.

Key features of the study:

• This report provides in-depth analysis of the global renal biomarkers market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
• It profiles leading players in the global renal biomarkers market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Beckman Coulter, Inc., (Danaher Corporation), Thermo Fisher Scientific Inc., Abbott Laboratories, BIOPORTO A/S, Astute Medical, Inc., Randox Laboratories Ltd., and SphingoTec GmbH.
• Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
• The global renal biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

• Global Renal Biomarkers Market, By Biomarker Type:
  • Functional Biomarker
• Serum Creatinine
• Serum Cystatin C
• Urine Albumin
  • Up-Regulated Proteins
• Neutrophil gelatinase-associated lipocalin
• Kidney injury molecule 1
• Interleukin 18
  • Others
• Global Renal Biomarkers Market, By Technique:
  • Enzyme Linked Immunosorbent Assay
  • Particle-Enhanced Turbidimetric Immunoassay
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay
  • Liquid Chromatography-Mass Spectrometry
• Global Renal Biomarkers Market, By End User:
  • Diagnostic Labs
  • Outpatient Clinics
  • Research Centers
  • Hospitals
• Global Renal Biomarkers Market, By Geography:
  • North America
• By Biomarker Type
  • Functional Biomarker
    • Serum Creatinine
    • Serum Cystatin C
    • Urine Albumin
  • Up-Regulated Proteins
    • Neutrophil gelatinase-associated lipocalin
    • Kidney injury molecule 1
    • Interleukin 18
  • Others
• By Technique
  • Enzyme Linked Immunosorbent Assay
  • Particle-Enhanced Turbidimetric Immunoassay
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay
  • Liquid Chromatography-Mass Spectrometry
• By End User
  • Diagnostic Labs
  • Outpatient Clinics
  • Research Centers
  • Hospitals
• By Country:
  • U.S.
  • Canada
  • Europe
• By Biomarker Type
  • Functional Biomarker
    • Serum Creatinine
    • Serum Cystatin C
    • Urine Albumin
  • Up-Regulated Proteins
    • Neutrophil gelatinase-associated lipocalin
    • Kidney injury molecule 1
    • Interleukin 18
  • Others
• By Technique
  • Enzyme Linked Immunosorbent Assay
  • Particle-Enhanced Turbidimetric Immunoassay
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay
  • Liquid Chromatography-Mass Spectrometry
• By End User
  • Diagnostic Labs
  • Outpatient Clinics
  • Research Centers
  • Hospitals
• By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
• By Biomarker Type
  • Functional Biomarker
    • Serum Creatinine
    • Serum Cystatin C
    • Urine Albumin
  • Up-Regulated Proteins
    • Neutrophil gelatinase-associated lipocalin
    • Kidney injury molecule 1
    • Interleukin 18
  • Others
• By Technique
  • Enzyme Linked Immunosorbent Assay
  • Particle-Enhanced Turbidimetric Immunoassay
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay
  • Liquid Chromatography-Mass Spectrometry
• By End User
  • Diagnostic Labs
  • Outpatient Clinics
  • Research Centers
  • Hospitals
• By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
• By Biomarker Type
  • Functional Biomarker
    • Serum Creatinine
    • Serum Cystatin C
    • Urine Albumin
  • Up-Regulated Proteins
    • Neutrophil gelatinase-associated lipocalin
    • Kidney injury molecule 1
    • Interleukin 18
  • Others
• By Technique
  • Enzyme Linked Immunosorbent Assay
  • Particle-Enhanced Turbidimetric Immunoassay
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay
  • Liquid Chromatography-Mass Spectrometry
• By End User
  • Diagnostic Labs
  • Outpatient Clinics
  • Research Centers
  • Hospitals
• By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East:
• By Biomarker Type
  • Functional Biomarker
    • Serum Creatinine
    • Serum Cystatin C
    • Urine Albumin
  • Up-Regulated Proteins
    • Neutrophil gelatinase-associated lipocalin
    • Kidney injury molecule 1
    • Interleukin 18
  • Others
• By Technique
  • Enzyme Linked Immunosorbent Assay
  • Particle-Enhanced Turbidimetric Immunoassay
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay
  • Liquid Chromatography-Mass Spectrometry
• By End User
  • Diagnostic Labs
  • Outpatient Clinics
  • Research Centers
  • Hospitals
• By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
• By Biomarker Type
  • Functional Biomarker
    • Serum Creatinine
    • Serum Cystatin C
    • Urine Albumin
  • Up-Regulated Proteins
    • Neutrophil gelatinase-associated lipocalin
    • Kidney injury molecule 1
    • Interleukin 18
  • Others
• By Technique
  • Enzyme Linked Immunosorbent Assay
  • Particle-Enhanced Turbidimetric Immunoassay
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay
  • Liquid Chromatography-Mass Spectrometry
• By End User
  • Diagnostic Labs
  • Outpatient Clinics
  • Research Centers
  • Hospitals
• By Country/Region:
  • Central Africa
  • South Africa
  • North Africa
• Company Profiles
  • Beckman Coulter, Inc.*
• Company Overview
• Product Portfolio
• Financial Performance
• Key Strategies
• Recent Developments
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • BIOPORTO A/S
  • Astute Medical, Inc.
  • Randox Laboratories Ltd.
  • SphingoTec GmbH

"*" marked represents similar segmentation in other categories in the respective section.